Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly ...
Clinical research supports an estimated $20.2 billion in annual economic activity in the state, but challenges are growing.
Japan’s Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for ...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupix ...
Pathophysiologic biomarkers for chronic spontaneous urticaria (CSU) are emerging, which can help better target therapies for the potentially debilitating condition.
Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...
Enveda, a multi-asset clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life's chemistry, today announced that the US ...
Achieving equitable access to anti-fibrotic drugs requires multi-stakeholder collaboration, while the most critical unmet clinical need remains overcoming late and misdiagnosis through targeted ...
Like priests or your own lawyer, doctors are in that category of people where, technically, you should feel safe to share ...
In 2024, the city’s greenhouse gas emissions dropped to levels not seen since 2020, during the COVID-19 pandemic — a sign, environmentalists say, that new climate policies are making a difference. The ...
The dual initiative concluded with a shared message - clean air, mental clarity, and informed lifestyle choices are vital for preventive health. By bridging medical science, technology, and mindful ...